Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

Biogen (0R1B)

Biogen Inc
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:0R1B
DateTimeSourceHeadlineSymbolCompany
06/03/202412:30UK RegulatoryNew Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene TherapyLSE:0R1BBiogen Inc
04/03/202421:15UK RegulatoryBiogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual MeetingLSE:0R1BBiogen Inc
23/02/202412:00UK RegulatoryBiogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMPLSE:0R1BBiogen Inc
12/02/202421:06UK RegulatoryBiogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s AtaxiaLSE:0R1BBiogen Inc
31/01/202412:30UK RegulatoryBiogen to Realign Resources for Alzheimer's Disease FranchiseLSE:0R1BBiogen Inc
06/08/202317:07Alliance NewsAlliance NewsCORRECT: Biogens, Sage Therapeutics postpartum depression drug okayedLSE:0R1BBiogen Inc
06/08/202314:17Alliance NewsAlliance NewsBiogens, Sage Therapeutics postpartum depression treatment approvedLSE:0R1BBiogen Inc
09/06/202312:12Alliance NewsAlliance News*Nasdaq halts trading of Biogen stockLSE:0R1BBiogen Inc
13/01/202014:28Alliance NewsAlliance NewsPfizer Could Net USD635 Million As Biogen Acquires Alzheimer's DrugLSE:0R1BBiogen Inc
 Showing the most relevant articles for your search:LSE:0R1B